Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9986021 | 0.85 | CYP1A2 (0.30) | CYP1A2 | |
| SCHEMBL2043119 | 0.80 | CYP1A2 (0.42) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL9985093 | 0.74 | — | — | |
| SCHEMBL14390606 | 0.73 | ALDH1A1 (0.53) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL225199 | 0.72 | ALDH1A1 (0.57) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL19218042 | 0.66 | HSD11B1 (0.34) | — | |
| SCHEMBL10573301 | 0.65 | ALDH1A1 (0.52) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL9985898 | 0.65 | PTGS2 (0.30) | — | |
| SCHEMBL7905900 | 0.64 | ALDH1A1 (0.39) | CYP1A2ALDH1A1LMNATSHR | |
| SCHEMBL17256628 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585444-B1 | AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| EP-2585444-B1 | AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8765744-B2 | Azaspirohexanones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765744-B2 | Azaspirohexanones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765744-B2 | Azaspirohexanones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| EP-2585444-A1 | AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20120190675-A1 | Azaspirohexanones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190675-A1 | Azaspirohexanones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190675-A1 | Azaspirohexanones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| WO-2011161128-A1 | AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011161128-A1 | AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190675-A1 | Azaspirohexanones | HSD11B1, HSD3B1, HSD17B1 | CYP1A2 58/4885USP2 2288/4885ALDH1A1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.